/ Lupin Gets FDA Approval For Its Generic Drug ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Friday, 3 February 2017

Lupin Limited, a major pharmaceutical company announced today that it has received final approval from Unites States Food and Drug Administration (FDA).

The approval is for the marketing of its Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. The cream is a generic equivalent Mylan Pharmaceuticals Inc.’s Triamcinolone Acetonide Cream, 0.025% and 0.1%.

Lupin will soon start the promotion of the product. The product provides relief to the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Lupin develops and delivers a broad range of generic formulations, APIs and biotechnology products globally. Lupin Ltd is currently trading at Rs 1488.25, up by Rs 4.7 or 0.32% from its previous closing of Rs 1483.55 on the BSE.

The scrip opened at Rs 1485 and has touched a high and low of Rs 1505.35 and Rs 1479.05 respectively. So far 514726(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 66981.59 crore.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1911.55 on 09-Feb-2016 and a 52 week low of Rs 1294.05 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs 1516.25 and Rs 1436 respectively.

The promoters holding in the company stood at 46.71 % while Institutions and Non-Institutions held 41.46 % and 11.83 % respectively. The stock is currently trading below its 200 DMA.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717